🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-521480-12-00
Authorised Phase I

A Phase 1 Study of ATV-1601, in Patients with Advanced Cancer that have AKT1 E17K Mutations

2025-521480-12-00 · tracked via the Priya Life Science EU tracker
Sponsor
Atavistik Bio Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
15/09/2025
Enrollment target
64
Sites
Belgium, Italy, Spain, France

Condition studied

Advanced solid tumors, Breast Cancer

Eligibility

Age group
18-64 years, 65+ years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521480-12-00 on CTIS ↗ ← All trials in the EU